| Drug-Target Information | ||||||||
|---|---|---|---|---|---|---|---|---|
| Drug Name | Target Name | Drug Type | Target Type | Source | Drug MeSHID | Interaction Score | Drug Status | Target Action |
| avastin+/-tarceva | arachidonate 5-lipoxygenase | NA | Successful target | TTD , DGIDB | Non-Small Cell Lung Carcinoma[MeSHID:D002289] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Nasopharyngeal carcinoma[MeSHID:C538339] |
NA | phase 3 | unknown |
| avastin+/-tarceva | m-phase inducer phosphatase 2 | NA | Clinical trial target | TTD , DGIDB | Non-Small Cell Lung Carcinoma[MeSHID:D002289] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Nasopharyngeal carcinoma[MeSHID:C538339] |
NA | phase 3 | unknown |
| avastin+/-tarceva | dual specificity protein phosphatase 1 | NA | Clinical trial target | TTD , DGIDB | Non-Small Cell Lung Carcinoma[MeSHID:D002289] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Nasopharyngeal carcinoma[MeSHID:C538339] |
NA | phase 3 | unknown |
| avastin+/-tarceva | indoleamine 2,3-dioxygenase 1 | NA | Successful target | TTD , DGIDB | Non-Small Cell Lung Carcinoma[MeSHID:D002289] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Nasopharyngeal carcinoma[MeSHID:C538339] |
NA | phase 3 | unknown |
| avastin+/-tarceva | rotamase pin1 | NA | Clinical trial target | TTD , DGIDB | Non-Small Cell Lung Carcinoma[MeSHID:D002289] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Nasopharyngeal carcinoma[MeSHID:C538339] |
NA | phase 3 | unknown |
| avastin+/-tarceva | vascular endothelial growth factor a | NA | Successful target | TTD , DGIDB | Non-Small Cell Lung Carcinoma[MeSHID:D002289] Disruptive Impulse Control and Conduct Disorders[MeSHID:D007174] Nasopharyngeal carcinoma[MeSHID:C538339] |
NA | phase 3 | unknown |
| click here to return to the previous page | ||||||||